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Abstract
Background
The extent to which the presence and extent of subclinical atherosclerosis by coronary
computed tomography angiography influences a potential mortality benefit of statin is
unknown. We evaluated the relationship between statin therapy, mortality, and subclinical
atherosclerosis.
Methods
In the CONFIRM study, patients with normal or non-obstructive plaque (<50% diameter ste-
nosis) for whom data on baseline statin use was available were included. Coronary artery
calcium (CAC) was quantified using the Agatston score. The extent of non-obstructive coro-
nary atherosclerosis was quantified using the segment involvement score (SIS). 8,016
patients were followed for a median of 2.5 years with analysis of all-cause mortality and
major adverse cardiac events (MACE) including all-cause mortality, myocardial infarction,
unstable angina, target vessel revascularization, and coronary artery disease-related
hospitalization.
Results
1.2% of patients experienced all-cause mortality. Patients not on baseline statin therapy had
a stepwise increased risk of all-cause mortality by CAC (relative to CAC = 0; CAC 1–99: haz-
ard ratio [HR] 1.65, CAC 100–299: HR 2.19, and CAC�300: HR 2.98) or SIS (relative to
SIS = 0; SIS 1: HR 1.62, SIS 2–3: 2.48 and SIS�4: 2.95). Conversely, in patients on base-
line statin therapy, there was no significant increase in mortality risk with increasing CAC
(p value for interaction = 0.049) or SIS (p value for interaction = 0.007). The incidence of
MACE was 2.1%. Similar to the all-cause mortality, the risk of MACE was increased with
CAC or SIS strata in patient not on baseline statin therapy. However, this relation was not
observed in patient on baseline statin therapy.
Conclusion
In individuals with non-obstructive coronary artery disease, increased risk of adverse events
occurs with increasing CAC or SIS who are not on baseline statin therapy. Statin therapy is
associated with a mitigation of risk of cardiac events in the presence of increasing athero-
sclerosis, with no particular threshold of disease burden.
Introduction
Coronary artery calcium (CAC) scoring is a robust method for risk prediction of major
adverse cardiac events (MACE), and current societal guidelines recommend a threshold of
�300 Agatston units for consideration of statin treatment [1]. Coronary computed tomo-
graphic angiography (CCTA) is a contrast-enhanced anatomic imaging method that permits
direct visualization of both calcified and non-calcified atherosclerotic plaque that also allows
for effective prognostication of risk of MACE [2–7]. In patients with non-obstructive coronary
Statin therapy in early coronary artery disease
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artery disease (CAD) by CCTA, the comparative effect of statin therapy on MACE for individ-
uals with evident CAC or atherosclerotic plaque by CCTA is unknown. Thus, in a prospective
multinational cohort of individuals undergoing CAC and CCTA without obstructive CAD, we
sought to identify whether there was a threshold of CAC- and CCTA-identified CAD wherein
statin therapy was associated with reduced mortality risk.
Materials and methods
Study population
Details of the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An
InteRnational Multicenter) study have been described elsewhere [8]. In brief, 27,125 consecu-
tive patients enrolled in this global multicenter cardiac CT registry underwent coronary
CCTA at 12 cluster sites in 6 countries (Canada, Germany, Italy, Korea, Switzerland, United
States) between February 2003 and December 2009. Patients with a history of myocardial
infarction or coronary revascularization (coronary artery bypass and/or percutaneous coro-
nary intervention) (n = 2,350), or congenital heart disease (n = 111) were excluded from analy-
sis. A further 16,648 patients were excluded including those with obstructive CAD (�50%
luminal diameter stenosis) as diagnosed by CCTA (n = 5,594), and those with missing data
regarding the use of statins (n = 9,815), risk factors (n = 239), or CAC (n = 1000) were also
excluded. A total of 8,016 patients met the inclusion criteria and comprised the study sample
(Fig 1). The Institutional Review Board of Weil Cornell Medical College approved the study
and its procedures, including coordination with other ethics committees. Each of the contrib-
uting centers received ethics approval from their respective institutional review boards, and
written informed consent was obtained from the study participants.
Study variables
At the time of CCTA examination, patient’s information was prospectively collected and
recorded in site-specific case report forms (CRFs). Patients treated for or with a prior diagnosis
Fig 1. Flow diagram for patient enrollment. A total of 8,016 patients met the inclusion criteria.
https://doi.org/10.1371/journal.pone.0207194.g001
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of hypertension, diabetes, or dyslipidemia, a family history of premature CAD or a history of
smoking were categorized as having that cardiovascular risk factor. Specifically, systemic arte-
rial hypertension was defined as a documented history of high blood pressure or treatment
with antihypertensive medication. Diabetes mellitus was defined as diagnosis of diabetes con-
firmed previously by a physician and/or use of insulin or oral hypoglycemic agents. Dyslipide-
mia was defined as known but untreated dyslipidemia or current treatment with lipid-
lowering medications. A family history of premature CAD was defined as a primary relative
with a diagnosis early in life (i.e., mother <65 years of age or father <55 years of age). A posi-
tive smoking history was defined as current smoking or cessation of smoking within 3 months
of examination. Self-reported use of statin medication was evaluated at the time of enrolment.
Definition of CCTA measures
Image data were acquired by CT scanners of�64-detector rows. Patient preparation, acquisi-
tion, and interpretation of CCTA and CAC score data were performed in accordance with the
Society of Cardiovascular Computed Tomography Guidelines [9]. For the present analysis,
coronary stenoses were defined as none (0% stenosis without plaque) and non-obstructive (1–
49% diameter stenosis) CAD. The CAC score was determined based on the scoring system
described by Agatston et al. [10]. The CAC score was categorized into 4 strata as: 0, 1–99, 100–
299, and�300 according to current guidelines [11]. The extent of atherosclerotic burden was
determined by a segment-involvement score (SIS) based on a 16-segment coronary model,
which reflects the number of coronary segments possessing atherosclerotic plaque (mini-
mum = 0; maximum = 16) [12]. SIS was also categorized as 0, 1, 2–3, and�4 segments in the
current study population.
Patient follow-up
Primary endpoint was all-cause mortality and secondary endpoint was major adverse cardiac
events (MACE). According to the study protocol, MACE was defined as all-cause mortality,
myocardial infarction, unstable angina, target vessel revascularization, and CAD-related hospi-
talization. Event data were ascertained at each local institution by direct patient query, through
medical records at non-US sites or national all-cause mortality records at US sites. Data coor-
dinating center and independent biostatistician checked the database to enhance data quality,
and they only knew the participants only by study identifier number.
Statistical methods
Continuous variables are presented as means with standard deviations, and categorical vari-
ables as counts with proportions. Between-group differences according to statin use were com-
pared by use of a Wilcoxon rank-sum test for continuous variables, and chi-square test for
categorical variables. Unadjusted comparisons of the primary outcome according to the pres-
ence and magnitude of the CAC and SIS scores stratified by statin therapy were performed
using Kaplan-Meier survival curves with log-rank tests. A multivariable Cox proportional
regression model reporting hazard ratios with 95% confidence intervals (95% CI) was
employed to examine differences in the risk of all-cause mortality and MACE according to
statin therapy, while adjusting for age, gender, and traditional cardiovascular risk factors such
as hypertension, diabetes mellitus, dyslipidemia, family history and current smoking. All statis-
tical analyses were performed using SPSS (version 19.0.0, IBM, New York). A two-tailed p
value <0.05 was considered statistically significant.
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Results
Study population
Of 8,016 patients, the incidence of all-cause mortality was 1.2% (99 events) and that of MACE
was 2.1% (165 events) during a median follow-up of 2.5 years. Baseline characteristics of the
study cohort are presented in Tables 1 and 2. Patients on baseline statin therapy tended to be
older and have more CAD risk factors (p<0.001 for all) compared with those who were not
on statin therapy. Both higher CAC and SIS scores were associated with older age as well as a
higher prevalence of hypertension, diabetes mellitus, and dyslipidemia.
CAC and statin therapy
In the overall population, there was a stepwise increased risk of all-cause mortality by strata of
CAC after adjustment for covariates (Table 3). This association was influenced by the presence
of baseline statin therapy (Fig 2, Table 3). Specifically, the stepwise relationship between
increasing CAC and increased mortality was preserved in patients not on baseline statin ther-
apy. However, there was no significant association between individual strata of CAC and all-
cause mortality after adjustment for clinical variables, although there was a borderline associa-
tion of increased risk for CAC�300 (HR = 3.05, 95% CI 0.92–10.09, p = 0.07). As compared to
patients taking statins, patients not on statin therapy had significantly higher risks of all-cause
mortality according to increasing CAC strata except for those with CAC�300 (p value for
interaction = 0.049).
Although the risk of MACE was increased by strata of CAC in the overall population, this
finding was attenuated according to the baseline statin therapy (Table 4).
SIS and statin therapy
In the overall population, there was a stepwise increased risk of all-cause mortality by increas-
ing strata of SIS after adjustment of covariates (Table 3). Compared to patients with SIS = 0,
Table 1. Baseline characteristics.
Overall Without statin With statin p value
(N = 8016) (N = 5551) (N = 2465)
Age 57.1±11.8 55.6±12.2 60.7±10.2 <0.001
Male gender 4152 (51.8) 2895 (52.2) 1257 (51.0) 0.338
Hypertension 3930 (49.0) 2513 (45.3) 1417 (57.5) <0.001
Diabetes mellitus 978 (12.2) 530 (9.5) 448 (18.2) <0.001
Dyslipidemia 4544 (56.7) 2500 (45.0) 2044 (82.9) <0.001
Family history 1982 (24.7) 1294 (23.3) 688 (27.9) <0.001
Current smoking 1277 (15.9) 917 (16.5) 360 (14.6) 0.031
Body mass index 26.3±4.7 26.3±4.8 26.3±4.7 0.688
Renal insufficiency 16 (0.2) 10 (0.2) 6 (0.2) 0.591
Peripheral vascular disease 112 (1.4) 83 (1.5) 29 (1.2) 0.205
Cerebrovascular disease 73 (0.9) 51 (0.9) 22 (0.9) 0.965
Total cholesterol 191.8±43.0 192.4±42.9 190.3±43.1 0.089
LDL cholesterol 118.0±35.8 118.3±36.3 117.3±34.6 0.332
HDL cholesterol 53.6±16.3 53.9±16.6 53.1±15.6 0.066
CAC 65.6±242.1 46.8±198.6 108.1±314.9 <0.001
SIS 1.0±1.7 0.7±1.5 1.5±2.0 <0.001
LDL, low-density lipoprotein; HDL, high-density lipoprotein; CAC, coronary artery calcium; SIS, segment involvement score.
https://doi.org/10.1371/journal.pone.0207194.t001
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patients with SIS>1 was associated with higher risk of all-cause mortality (p<0.05). This asso-
ciation was influenced by the presence of baseline statin therapy (Fig 2, Table 3). Relative to
those with SIS = 0 not taking baseline statins, the adjusted risk of all-cause mortality increased
stepwise with increasing SIS, with significantly increased mortality hazard for SIS 2–3 and SIS
�4. Conversely, this stepwise association was attenuated by the presence of baseline statin
therapy (p value for interaction = 0.007). An increased mortality hazard was not observed in
patients with any degree of SIS on baseline statin therapy.
Table 2. Baseline characteristics by CAC or SIS categories.
CAC 0 CAC 1–99 CAC 100–299 CAC�300 p value SIS 0 SIS 1 SIS 2–3 SIS�4 p value
(N = 4858) (N = 2060) (N = 623) (N = 475) (N = 4969) (N = 1254) (N = 1097) (N = 696)
Age 53.5±11.5 60.9±9.9 65.1±9.1 68.0±9.4 <0.001 54.0±11.6 60.3±10.4 62.3±9.9 65.6±10.1 <0.001
Male gender 2273 (46.8) 1190 (57.8) 381 (61.2) 308 (64.8) <0.001 2343 (47.2) 698 (55.7) 668 (60.9) 443 (63.6) <0.001
Hypertension 2128 (43.8) 1136 (55.1) 366 (58.7) 300 (63.2) <0.001 2204 (44.4) 665 (53.0) 611 (55.7) 450 (64.7) <0.001
Diabetes mellitus 423 (8.7) 338 (16.4) 111 (17.8) 106 (22.3) <0.001 461 (9.3) 173 (13.8) 198 (18.0) 146 (21.0) <0.001
Dyslipidemia 2561 (52.7) 1277 (62.0) 422 (67.7) 284 (59.8) <0.001 2620 (52.7) 782 (62.4) 684 (62.4) 458 (65.8) <0.001
Family history 1176 (24.2) 507 (24.6) 169 (27.1) 130 (27.4) 0.219 1195 (24.0) 290 (23.1) 322 (29.4) 175 (25.1) 0.001
Current smoking 757 (15.6) 327 (15.9) 103 (16.5) 90 (18.9) 0.279 777 (15.6) 202 (16.1) 174 (15.9) 124 (17.8) 0.532
Body mass index 26.4±4.8 26.0±4.5 26.2±5.0 26.2±4.7 0.012 26.4±4.7 26.2±4.9 26.1±4.9 25.9±4.6 0.007
Renal insufficiency 9 (0.2) 5 (0.2) 1 (0.2) 1 (0.2) 0.968 8 (0.2) 3 (0.2) 5 (0.5) 0 0.201
Peripheral vascular disease 70 (1.4) 22 (1.1) 9 (1.4) 11 (2.3) 0.259 66 (1.3) 22 (1.8) 11 (1.0) 13 (1.9) 0.242
Cerebrovascular disease 38 (0.8) 17 (0.8) 8 (1.3) 10 (2.1) 0.187 33 (0.7) 16 (1.3) 12 (1.1) 12 (1.7) 0.201
Total cholesterol 194.5±45.0 187.7±39.8 183.8±37.0 189.6±37.1 <0.001 194.2±45.1 187.3±42.1 187.3±34.5 187.2±36.6 <0.001
LDL cholesterol 119.8±37.3 115.6±33.1 112.2±31.3 116.0±32.5 <0.001 119.8±38.0 114.1±31.7 114.9±29.2 115.6±31.5 <0.001
HDL cholesterol 54.4±16.6 52.2±15.9 52.9±16.4 52.4±13.8 <0.001 54.0±16.4 53.6±16.9 53.0±15.8 52.2±15.1 0.115
CAC 0 29.9±27.4 174.9±56.3 748.1±671.9 <0.001 9.7±123.5 45.4±141.8 121.3±239.9 413.8±538.8 <0.001
SIS 0.2±0.6 1.4±1.4 3.0±2.0 4.5±2.5 <0.001 0 1.0±0.0 2.4±0.5 5.4±1.7 <0.001
LDL, low-density lipoprotein; HDL, high-density lipoprotein; CAC, coronary artery calcium; SIS, segment involvement score.
https://doi.org/10.1371/journal.pone.0207194.t002
Table 3. Adjusted association between all-cause mortality, CAC, SIS, and baseline statin therapya.
Overall population Without statin therapy With statin therapy
Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
p value
CAC 0 1.00 1.00 1.00
CAC 1–99 1.29
(0.76–2.17)
0.346 1.65
(0.92–2.95)
0.097 0.56
(0.17–1.91)
0.357
CAC 100–299 1.90
(1.00–3.61)
0.052 2.19
(1.04–4.65)
0.041 1.19
(0.34–4.19)
0.789
CAC�300 2.86
(1.55–5.27)
<0.001 2.98
(1.44–6.16)
0.004 3.05
(0.92–10.09)
0.068
SIS 0 1.00 1.00 1.00
SIS 1 1.54
(0.85–2.78)
0.154 1.62
(0.81–3.24)
0.171 1.37
(0.44–4.29)
0.586
SIS 2–3 2.25
(1.32–3.83)
0.003 2.48
(1.34–4.61)
0.004 1.62
(0.56–4.71)
0.375
SIS�4 2.07
(1.13–3.77)
0.019 2.95
(1.50–5.81)
0.002 0.84
(0.21–3.33)
0.800
CAC, coronary artery calcium; SIS, segment involvement score.
aAdjusted for age, male gender, hypertension, diabetes mellitus, dyslipidemia, family history and current smoking.
https://doi.org/10.1371/journal.pone.0207194.t003
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A stepwise increased risk of MACE by increasing strata of SIS was also observed in the over-
all population (Table 4). Compared to patients with SIS = 0, patients with SIS�1 was associ-
ated with higher risk of MACE (p<0.05). Relative to those with SIS = 0 not taking baseline
statins, the adjusted risk of MACE was significantly increased in patients with SIS�1. How-
ever, this association was abated in patients with statin therapy.
Fig 2. Kaplan-Meier survival curves for all-cause mortality-free survival. (A) coronary artery calcium score
categories for patients without statin therapy, (B) coronary artery calcium score categories for patients with statin
therapy, (C) segment involvement score categories for patients without statin therapy, and (D) segment involvement
score categories for patients with statin therapy. Blue, green, orange, and red lines indicate 0, 1–99, 100–299, and�300
coronary artery calcium score categories. Blue, green, orange, and red lines indicate 0, 1, 2–3, and�4 segment
involvement score categories.
https://doi.org/10.1371/journal.pone.0207194.g002
Table 4. Adjusted association between major adverse cardiac events (MACE)a, CAC, SIS, and baseline statin therapyb.
Overall population Without statin therapy With statin therapy
Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
p value
CAC 0 1.00 1.00 1.00
CAC 1–99 1.62
(1.07–2.45)
0.022 2.15
(1.30–3.56)
0.003 0.76
(0.36–1.59)
0.462
CAC 100–299 2.64
(1.60–4.37)
<0.001 2.54
(1.28–5.01)
0.007 2.16
(1.03–4.55)
0.042
CAC�300 4.63
(2.87–7.45)
<0.001 4.91
(2.65–9.11)
<0.001 3.84
(1.81–8.13)
<0.001
SIS 0 1.00 1.00 1.00
SIS 1 2.22
(1.43–3.47)
<0.001 1.82
(1.02–3.24)
0.043 2.65
(1.30–5.43)
0.008
SIS 2–3 2.84
(1.85–4.37)
<0.001 3.13
(1.86–5.27)
<0.001 1.95
(0.91–4.18)
0.088
SIS�4 3.48
(2.18–5.55)
<0.001 3.19
(1.75–5.82)
<0.001 3.54
(1.67–7.48)
0.001
CAC, coronary artery calcium; SIS, segment involvement score.
aMACE was defined as a composite of all-cause mortality, myocardial infarction, unstable angina, target vessel revascularization, and coronary artery disease-related
hospitalization
bAdjusted for age, male gender, hypertension, diabetes mellitus, dyslipidemia, family history and current smoking.
https://doi.org/10.1371/journal.pone.0207194.t004
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Discussion
In this prospective multinational cohort study of individuals undergoing CCTA, we identified
a stepwise increased risk of all-cause mortality for individuals with increasing atherosclerotic
burden despite the absence of anatomically obstructive CAD. Importantly, this association was
modified by the presence or absence of baseline statin therapy. In contrast to individuals not
on baseline statin therapy, the baseline use of statins was associated with a mitigation of
increased mortality risk despite the presence or burden of non-obstructive atherosclerosis.
These findings support the notion that statins may be beneficial in even patients with lower
degrees of subclinical atherosclerosis as detected by CCTA.
Prior evidence has demonstrated that a substantial proportion of cardiac events arise from
non-obstructive coronary stenoses [13, 14]. For instance, the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the Coronary Tree) study observed that many
cardiac events arise from angiographic non-culprit lesions, especially those with high plaque
burden and thin-cap fibroatheroma detected by gray-scale intravascular ultrasound [15]. Lon-
gitudinal data has further demonstrated an increased event risk in patients with non-obstruc-
tive CAD as detected by invasive angiography or CCTA [16, 17]. Accordingly, the present
investigation of patients with non-obstructive CAD observed an incremental occurrence of
mortality according to increasing CAC or SIS in patients not on statin therapy. These findings
are clinically significant, in that most conventional testing (e.g. stress testing) for CAD may
not detect non-obstructive atherosclerosis.
In the past decade, numerous randomized controlled trials have documented that statin
therapy not only prevents cardiovascular events but also Finimproves survival in patients with
varying degrees of clinical CAD, although these trials did not specifically study patients with
anatomically non-obstructive CAD [18–21]. Statins are the leading candidate for pharmaco-
logic prevention in such patients based on the observation that statins could slow disease pro-
gression and elicit stabilization of vulnerable plaque [22, 23]. Hoffmann et al. [24] evaluated
the influence of statins on plaque progression by volumetric measurement using CCTA, and
found that statins significantly slowed the growth of non-calcified plaques after adjusting for
LDL-C levels and cardiac risk factors. It can be argued that the importance of statin therapy in
non-significant stenosis was demonstrated in the FAME 2 (Fractional Flow Reserve versus
Angiography for Multivessel Evaluation 2) study, in which patients who had been deferred
with functionally non-significant lesions were treated to the target of LDL-C <70 mg/dl with
clinical outcomes as favorable as those associated with revascularization [25]. As well as plaque
stabilization and regression, statins act beneficially through different pleiotropic effects on
inflammation, fibrosis, endothelial function, thrombosis, and coagulation. Via these mecha-
nisms, statin might also contribute to the reduction in all-cause mortality.
In light of this evidence, recent guidelines suggest that high CAC (i.e., greater than 300
Agatston units) should be taken into incorporated into statin decision-making in certain pri-
mary prevention settings [1]. The results of the present study suggest potential benefit for
patients with even lower degrees of CAC or non-obstructive CAD by CCTA [26]. Importantly,
we identified no lower limit of CAC wherein statin therapy did not mitigate mortality risk.
These findings suggest that a binary cutoff of CAC�300 for guiding statin treatment may not
be warranted, as those with lower scores appear to also derive significant risk attenuation. Fur-
thermore, this attenuation of risk was also observed in patients with SIS>1 on baseline statins,
which extends the hypothesis that any degree of atherosclerosis by CCTA should factor into
statin decision-making.
In the use of statin for the primary prevention of cardiovascular disease, there is still the
issue of gender-dependent efficacy. Recent meta-analysis including 174,000 patients showed
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the effect of statin therapy on mortality and cardiac events were comparable among women
and men, matched for cardiovascular risk [27]. When we analyzed the association between
adverse events and statin according to gender, similar benefit for men and women was shown
(p value for interaction = 0.127).
This study is not without limitations. Because specific causes of death for each patient were
not uniformly available at all sites, this does not include the cause of death and was based on
the all-cause mortality not cardiovascular death. Although coronary heart disease remains the
most common cause of death in developed countries, it is not possible to enucleate the propor-
tion of deaths which are originated from cardiovascular cause. However, this endpoint is not
affected by bias from misclassification of cause of death. And risk factors such as hypertension,
diabetes mellitus, dyslipidemia and smoking can contribute to all-cause mortality via addi-
tional non-cardiovascular mechanisms. Therefore, the primary endpoint of this study can be
an appropriate endpoint to follow. Information regarding statin use only was available for the
baseline time point. Analysis according to the treatment patterns of statin can be useful to
understand the mitigation of cardiac events. However, data were lacking with regards to statin
type and dosage, treatment indication, and duration of therapy. Further, changes in statin
medication use that may have occurred beyond baseline CCTA were unavailable. However,
that post-test initiation of statins in patients with newly discovered atherosclerosis would likely
have resulted in a greater attenuation in risk and a reduction in differences. It is further doubt-
ful that patients on statins at baseline with had evidence of atherosclerotic plaque by CCTA
would have had their treatment stopped. Finally, there was the lack of follow-up CCTA to eval-
uate the progression (or regression) of atherosclerotic burden or change of plaque composition
based on statin therapy. In a previous publication, statin use was associated with an increased
prevalence and burden of coronary plaques possessing calcium [28]. However, the serial asso-
ciation of plaque composition type to the longitudinal effect of statin was not also addressed.
Repeat CCTA for such reasons is not clinically recommended at this point. Although the
observational design of the study renders our findings hypothesis-generating, the large multi-
national cohort increases the generalizability of these findings and augments the paucity of
available literature on this topic. Additional large-scale randomized controlled trials designed
to evaluate the impact of early statin therapy on outcomes in patients with non-obstructive
CAD by CCTA appear warranted. Also, fractional flow reserve (FFR) CT can be useful to over-
come the limitation of CCTA to detect coronary stenosis. Current CT has decreased accuracy
in the setting of significant calcification and can’t evaluate lesion-specific ischemia. Therefore,
FFR CT-based temporal change of anatomy and physiology can be helpful to clarify the effect
of statin in CAD.
In conclusion, in this prospective multinational study of patients presenting with anatomi-
cally non-obstructive CAD, a heightened risk of adverse cardiac events including all-cause
mortality was observed with increasing CAC and SIS among patients not on statin therapy at
baseline. This stepwise risk was attenuated among patients on baseline statin therapy after
adjustment for clinical covariates. Although we await further confirmation, the current find-
ings are promising in that statin therapy may be associated with mitigating the risk of adverse
cardiac events among non-obstructive CAD patients, with no particular threshold of athero-
sclerotic disease burden.
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